Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07388615
Recruiting Phase 2

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

NCT07388615 · tracked via the Priya Life Science Egypt tracker
Sponsor
Al-Azhar University
Phase
Phase 2
Started
2026-01-18
Last updated
2026-02-05

Condition(s) studied

Cryptosporidium Infection

Investigational drug(s) / intervention(s)

Echinacea Extract

Echinacea Extract: Immulant ® (an extract derived from Echinacea purpurea plant)

Study summary

This study aims to:

1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children.
2. To measure the changes in parasite count in stool samples after treatment with Immulant ®.
3. To assess the safety and tolerability of Immulant ® in children participating in the study.

Eligibility

Sex
ALL
Min age
5 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of Cryptosporidiosis Disease * Age from 5-12 years * Immunocompromised children * Not receiving any drugs causing immunosuppression Exclusion Criteria: * Patients undergoing organ transplantation * Patients suffering from autoimmune diseases. * Patients suffering from hypersensitivity of this plant extract

Primary outcome measure(s)

  • To measure the changes in parasite count in stool samples after treatment — six months

Trial sites (1)

FacilityCityRegionStatus
National Nutritional Institute Cairo Egypt Recruiting

More Al-Azhar University trials in Egypt

"Augmented Reality-Assisted Miniscrew Placement in Orthodontics: A Clinical Trial" Starting soon
Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis Recruiting
Low-Intensity Shock Wave Therapy for Refractory Overactive Bladder in Women Starting soon
Management of Early Onset Scoliosis by Active Apex Correction Technique Recruiting
Comparative Dose-Response of Intrathecal Dexmedetomidine for Post-Spinal Shivering Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07388615 on ClinicalTrials.gov ↗ ← All trials in Egypt